Abstract:Gemcitabine (GEM) is among the most used chemotherapies for advanced malignancies including non-small cell lung cancer. The clinical efficacy of GEM is, however, downplayed by its poor bioavailability, short half-life, drug resistance, and dose-limiting toxicities (e.g. myelosuppression). In spite of many approaches exploited to improve the efficacy and safety of GEM, limited success was achieved. The short A6 peptide (sequence: Ac-KPSSPPEE-NH2) is clinically validated for specific binding to CD44 on metastatic tumors. Here, we designed a robust and CD44-specific GEM nanotherapeutics by encapsulating hydrophobic phosphorylated gemcitabine prodrug (HPG) into the core of A6 peptide-functionalized disulfide-crosslinked micelles (A6-mHPG), which exhibited reduction-triggered HPG release and specific targetability to CD44 overexpressing tumor cells. Interestingly, A6 greatly enhanced the internalization and inhibitory activity of micellar HPG (mHPG) in CD44 positive A549 cells, and increased its accumulation in A549 cancerous lung, leading to potent repression of orthotopic tumor growth, depleted toxicity, and marked survival benefits compared to free HPG and mHPG (median survival time: 59 days versus 30 and 45 days, respectively). The targeted delivery of gemcitabine prodrug with disulfide-crosslinked biodegradable micelles appears to be a highly appealing strategy to boost gemcitabine therapy for advance tumors. Statement of significance Gemcitabine (GEM) though widely used in clinics for treating advanced tumors is associated with poor bioavailability, short half-life and dose-limiting toxicities. Development of clinically translatable GEM formulations to improve its anti-tumor efficacy and safety is of great interest. Here, we report on CD44-targeting GEM nanotherapeutics obtained by encapsulating hydrophobic phosphorylated GEM prodrug (HPG), a single isomer of NUC-1031, into A6 peptide-functionalized disulfide-crosslinked micelles (A6-mHPG). A6-mHPG demonstrates stability against degradation, enhanced internalization and inhibition toward CD44+ cells, and increased accumulation in A549 lung tumor xenografts, leading to potent repression of orthotopic tumor growth, depleted toxicity and marked survival benefits. The targeted delivery of GEM prodrug using A6-mHPG is a highly appealing strategy to GEM cancer therapy. (c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer

A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Improving plasma stability and antitumor effect of gemcitabine via PEGylated liposome prepared by active drug loading

Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer

Development of Cationic Ph-Sensitive Liposomes with Gemcitabine Loading and Fucoidan-Coating Against Pancreatic Cancer Cells

Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma

Antitumor Gemcitabine Conjugated Micelles from Amphiphilic Comb-Like Random Copolymers

A cathepsin B-sensitive gemcitabine prodrug for enhanced pancreatic cancer therapy

Poly (L-Glutamic Acid)-G-methoxy Poly (ethylene Glycol)-Gemcitabine Conjugate Improves the Anticancer Efficacy of Gemcitabine.

Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy

Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction

In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

FU-coating Ph-Sensitive Liposomes for Improving the Release of Gemcitabine by Endosome Escape in Pancreatic Cancer Cells

Liposomal Nanostructures for Gemcitabine and Paclitaxel Delivery in Pancreatic Cancer.

Enhancement of Gemcitabine Against Pancreatic Cancer by Loading in Mesoporous Silica Vesicles

CD44-targeting Hydrophobic Phosphorylated Gemcitabine Prodrug Nanotherapeutics Augment Lung Cancer Therapy.

Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect.

Sustained delivery of gemcitabine via in situ injectable mussel-inspired hydrogels for the local therapy of pancreatic cancer